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Introduction
–Adrenergic receptors (ARs) are G protein–coupled recep-
tors that are powerful regulators of cardiac function (Rockman 
et al., 2002). Acute stimulation of -ARs physiologically aug-
ments cardiac contraction by increasing intracellular [Ca
2+]i, 
whereas chronic -AR stimulation promotes myocardial hyper-
trophy and heart failure (Koch et al., 2000; Lohse et al., 2003). 
An important -AR–stimulated signaling pathway implicated 
in the development of heart failure involves the multifunc-
tional  protein  kinase  Ca
2+/calmodulin  kinase  II  (CaMKII; 
Zhang and Brown, 2004; Anderson, 2009). Consistent with a 
pathogenic role, CaMKII activity and expression are increased 
in  animal  models  of  structural  heart  disease  (Zhang  et  al., 
2005; Yoo et al., 2009) and after chronic -AR stimulation 
(Zhu et al., 2003).
The mechanism of CaMKII activation after -AR stimula-
tion appears to be mediated through a pathway that involves the 
protein Epac (exchange protein directly activated by cAMP; Bos, 
2006; Oestreich et al., 2007, 2009). Epac is a cAMP-dependent 
guanine nucleotide exchange factor for the small GTPases Rap1 
and -2, which mediates cellular cAMP signaling independent   
of PKA (Bos, 2006; Ponsioen et al., 2009). Increasing intra-
cellular concentration of cAMP by -AR stimulation or with a 
cAMP analogue causes the Epac-mediated increase in CaMKII-
dependent  Ca
2+  cycling,  ryanodine  receptor  phosphorylation 
(Pereira et al., 2007), and diastolic sarcoplasmic reticulum (SR) 
Ca
2+ leak (Curran et al., 2007). Interestingly, despite similar 
levels of cAMP generation by both 1- and 2-AR subtypes, 
only 1-AR stimulation increases CaMKII activity (Wang et al., 
2004; Zhu et al., 2003; Yoo et al., 2009).
Although both 1- and 2-ARs stimulate adenylyl cy-
clase (AC) and generate the second messenger cAMP, consider-
able differences exist in the ability of these subtypes to activate   
downstream signaling pathways. For instance, CaMKII-dependent   
induction of fetal genes and apoptotic pathways in cardiac 
myocyte is mediated by 1-ARs but not 2-ARs (Zhu et al., 
2003; Sucharov et al., 2006). In contrast, stimulation of 2-ARs   
activates cell survival signals, whereas 1-ARs trigger car-
diomyocyte  apoptotic  pathways  (Communal  et  al.,  1999). 
Although the molecular mechanism for the -AR subtype 
specificity in activating CaMKII has not been fully elucidated, 
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2+/calmodulin  kinase  II  (CaMKII)  plays  an   
important role in cardiac contractility and the   
development of heart failure. Although stimulation 
of 1–adrenergic receptors (ARs) leads to an increase in   
CaMKII  activity,  the  molecular  mechanism  by  which   
1-ARs activate CaMKII is not completely understood. 
In this study, we show the requirement for the 1-AR regu-
latory protein -arrestin as a scaffold for both CaMKII   
and  Epac  (exchange  protein  directly  activated  by 
cAMP). Stimulation of 1-ARs induces the formation of a 
-arrestin–CaMKII–Epac1 complex, allowing its recruitment 
to the plasma membrane, whereby interaction with cAMP 
leads  to  CaMKII  activation.  -Arrestin  binding  to  the   
carboxyl-terminal tail of 1-ARs promotes a conforma-
tional change within -arrestin that allows CaMKII and 
Epac to remain in a stable complex with the receptor. 
The essential role for -arrestin and identification of the 
molecular mechanism by which only 1-ARs and not 2-ARs 
activate CaMKII significantly advances our understanding 
of this important cellular pathway.
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activity was significantly inhibited in the -arrestin KO mice 
compared with WT mice (Fig. 1 B).
Next, we used siRNA to specifically target -arrestin1 
or -2 or both and examined the contribution of each -arrestin   
isoform on -AR–mediated CaMKII activation. HEK-293 cells 
stably  expressing  WT–1-ARs  were  transfected  with  the 
-arrestin  siRNAs,  along  with  CaMKII-C  and  Flag-Epac1.   
Stimulation of 1-AR with ISO markedly elevated the level 
of pCaMKII in mock- and control siRNA–transfected cells   
(Fig. 1 C). In contrast, CaMKII activation was reduced in the 
presence of siRNA targeting either -arrestin1 or -2 and was 
completely inhibited when both -arrestin isoforms were knocked 
down (Fig. 1 C). Similar results were obtained with stimulation 
by 8-CPT (Fig. 1 D).
To further demonstrate the requirement of -arrestin for 
-AR–mediated CaMKII activation in the heart, we used trans-
genic (Tg) mice with cardiac-specific overexpression of a mu-
tant 1-AR that is unable to recruit -arrestin with agonist 
stimulation because it lacks G protein–coupled receptor kinase 
(GRK)  phosphorylation  sites  (GRK
–1-AR;  Rapacciuolo   
et al., 2003; Noma et al., 2007). ISO-mediated CaMKII acti-
vation was significantly increased in hearts of Tg mice over-
expressing WT–1-ARs but was unable to increase pCaMKII 
levels in hearts of Tg mice overexpressing GRK
–1-ARs 
(Fig.  2  A)  or  in  HEK-293  cells  with  stable  expression  of   
GRK
–1-ARs (Fig. 2 B). Collectively, these data demonstrate 
that -arrestin is required for agonist activation of CaMKII 
in vivo and in vitro and that this process uses both -arrestin1 
and -2 isoforms.
Stimulation  of  1-AR  stimulates AC  activity  via  the   
G protein Gs, leading to the generation of intracellular cAMP 
that directly activates Epac and CaMKII (de Rooij et al., 1998; 
Bos, 2006; Pereira et al., 2007). Consistent with these studies, 
we show that the activation of CaMKII in HEK-293 cells sta-
bly expressing WT–1-ARs can be mediated by forskolin (an 
activator of AC) and inhibited by CaMKII inhibitor KN-93.   
A specific PKA inhibitor (PKI) has no effect on either ISO- or 
8-CPT–mediated CaMKII activation (Fig. 2, C and D), confirm-
ing that 1-AR activates CaMKII in an Epac-dependent, PKA-
independent manner (Zhu et al., 2003; Oestreich et al., 2007).
-Arrestin forms a complex and colocalizes 
with CaMKII and Epac
To determine whether -arrestin serves as a scaffold for both 
CaMKII  and  Epac,  we  immunoprecipitated  either  CaMKII 
or Epac1 from heart homogenates of WT and -arrestin KO 
mice and immunoblotted for CaMKII, Epac1, and -arrestin. 
Under basal conditions, CaMKII was in complex with Epac1 
and -arrestin in hearts of WT mice, which was enhanced after 
stimulation with the agonists ISO or 8-CPT (Fig. 3 A). Loss of 
either -arrestin1 or -2 prevented the formation of a CaMKII– 
-arrestin–Epac1 complex in either unstimulated or agonist-
stimulated  conditions.  -Arrestin  could  still  associate  with 
Epac1 in the absence of CaMKII- (Fig. S1).
To determine the time course for this multimeric protein 
interaction, we used HEK-293 cells stably expressing WT–1-AR 
transiently transfected with either -arrestin1– (Fig. 3 B, left) 
amino acid sequence differences in the carboxyl-terminal tail 
(C-tail) between the 1- and 2-AR may be important. Indeed, 
studies have shown that 1- and 2-ARs have different PDZ 
(PSD-95/Dlg/ZO-1 homology domain)-binding motifs within   
their C-tail, leading to the recruitment of unique regulatory 
proteins with agonist stimulation. For example, the NHERF 
(Na
+/H
+ exchanger regulatory factor) binds to a DSLL motif in 
the C-tail of 2-ARs to stimulate Na
+/H
+ exchange (Hall et al., 
1998), whereas N-methyl-d-aspartate (NMDA) receptor binds to 
an ESKV motif within the C-tail of 1-ARs and promotes recep-
tor internalization (Hu et al., 2000). Interestingly, the C-tail of 
both -AR subtypes is critical for the recruitment of -arrestin,   
which is a molecule known to be an important receptor regula-
tory protein.
-Arrestins are key regulators of -AR endocytosis and 
trafficking.  -Arrestins  interact  with  agonist-occupied  and 
phosphorylated -ARs and inhibit further G protein activa-
tion (Ferguson et al., 1996). Beyond their classical function, 
-arrestins also function as scaffold proteins linking recep-
tors to several downstream effectors such as the MAPK cas-
cade (ERK [extracellular signal-regulated kinase] and JNK), 
Src, and the ubiquitin ligase Mdm2 (Lefkowitz and Shenoy, 
2005; Lefkowitz et al., 2006). -Arrestins are also known to 
bind to calmodulin (Wu et al., 2006) and to CaMKII- (Xiao   
et  al.,  2007).  Whether  -arrestin  is  required  for  1-AR– 
mediated  CaMKII  activation  is  not  known. Therefore,  we 
tested the hypothesis that -arrestin regulates activation of 
the CaMKII signaling pathway and provides specificity for 
CaMKII  signal  transduction  through  its  recruitment  to  the 
1-AR. We show that -arrestin scaffolds CaMKII and Epac, 
triggering translocation of this multimeric complex to agonist- 
occupied 1-ARs on the plasma membrane. Binding of -arrestin   
to the C-tail of the 1-AR induces a -arrestin conformation that 
stabilizes  the  -arrestin–CaMKII–Epac  interaction,  thereby 
permitting the activation of Epac by cAMP and subsequent 
CaMKII signaling.
Results
Isoproterenol (ISO)- and 8-pCPT-2-O-Me-
cAMP (8-CPT)–mediated CaMKII activation 
is -arrestin dependent
To test our hypothesis that activation of CaMKII is -arrestin 
dependent, we administered ISO or 8-CPT to wild-type (WT) 
and -arrestin knockout (KO) mice (Conner et al., 1997; Bohn 
et al., 1999). After ISO administration, the levels of phosphory-
lated CaMKII (pCaMKII; the active form of CaMKII) mark-
edly increased in hearts of WT mice, whereas ISO-mediated 
CaMKII phosphorylation was significantly inhibited in hearts 
from either -arrestin1 or -2 KO mice (Fig. 1 A). Infusion with 
8-CPT, a cAMP analogue which selectively activates Epac, 
resulted in a significant increase in pCaMKII in hearts of WT 
mice. In contrast, 8-CPT showed little effect on pCaMKII in 
either -arrestin1 or -2 KO mice. We also measured CaMKII 
activity using an in vitro kinase assay in heart extracts from 
WT and -arrestin KO mice. For both ISO and 8-CPT, CaMKII 575 -Arrestin links 1-AR–dependent CaMKII signaling • Mangmool et al.
Figure 1.  ISO and 8-CPT activate -arrestin–dependent CaMKII activity. (A and B) WT, -arrestin1 (-Arr1) KO and -arrestin2 KO mice were admin-
istered with saline (NS), 5 mg/kg ISO, or 2.5 mg/kg 8-CPT by i.v. infusion for 5 min. (A) LV homogenates were immunoblotted with anti-pCaMKII and 
anti-CaMKII antibodies. The CaMKII activation was quantified, expressed as fold increase over NS-treated WT mice, and shown as mean ± SEM (n = 5).   
(B) CaMKII kinase activity was determined under Ca
2+-dependent and -independent conditions. The CaMKII activity was quantified, expressed as fold 
increase over NS-treated WT mice, and shown as mean ± SEM (n = 5). (A and B) *, P < 0.01 versus NS-treated WT mice; 
#, P < 0.01 versus ISO-treated 
WT mice; 
‡, P < 0.01 versus 8-CPT–treated WT mice. (C and D) HEK-293 cells stably expressing WT–1-AR were transfected with CaMKII-C and Flag-
Epac1 alone (Mock) or with siRNAs targeting -arrestin1, -arrestin2, -arrestin1/2, or control siRNA. Serum-starved cells were stimulated at 37°C with 
10 µM ISO (C) or 5 µM 8-CPT (D). Cell lysates were then immunoprecipitated with anti-CaMKII antibody before blotting with anti-pCaMKII and anti-CaMKII 
antibodies. The CaMKII activation was quantified, expressed as fold increase over nonstimulated mock cells, and shown as mean ± SEM (n = 5). Inhibited 
ISO- and 8-CPT–mediated CaMKII activation were observed in cells transfected with -arrestin siRNA. *, P < 0.01 versus ISO-stimulated control siRNA;   
#, P < 0.05 versus 8-CPT–stimulated control siRNA. IP, immunoprecipitation; T-CaMKII, total CaMKII.JCB • VOLUME 189 • NUMBER 3 • 2010   576
Figure 2.  Stimulation of 1-AR activates CaMKII in a -arrestin–dependent and PKA-independent manner. (A) Tg mice overexpressing mouse WT–1-AR, 
GRK
–1-AR, or PKA
–1-AR were administered with saline (NS) or 5 mg/kg ISO by i.v. infusion for 5 min. LV homogenates were immunoblotted with anti-
pCaMKII and anti-CaMKII antibodies. The CaMKII activation was quantified, expressed as fold increase over NS-treated WT mice, and shown as mean ± SEM   
(n = 5). Increased ISO-mediated CaMKII was observed in WT–1-AR and PKA
–1-AR Tg mice. *, P < 0.01 versus nonstimulation; 
#, P < 0.01 versus ISO-
treated WT–1-AR Tg mice. (B) HEK-293 cells stably expressing GRK
–1-AR were transfected with CaMKII-C and Flag-Epac1. Serum-starved cells were 
stimulated with 10 µM ISO at 37°C. The CaMKII activation was quantified, expressed as fold increase over nonstimulated cells, and shown as mean ± SEM 
(n = 5). ISO stimulation of WT–1-AR is a positive control. *, P < 0.01 versus ISO stimulation of GRK
–1-AR. IP, immunoprecipitation. (C and D) HEK-293 cells 
stably expressing WT–1-AR were transfected with CaMKII-C and Flag-Epac1. Serum-starved cells were pretreated without or with PKI or KN-92 or -93 before 
stimulation with 10 µM ISO (C) or 5 µM 8-CPT (D) at 37°C. The CaMKII activation was quantified, expressed as fold increase over nonstimulated cells, and 
shown as mean ± SEM (n = 5). Inhibited ISO- and 8-CPT–mediated CaMKII activation were observed in cells pretreated with KN-93, a specific CaMKII inhibi-
tor, but not in cells pretreated with PKI. *, P < 0.01 versus ISO stimulation; 
#, P < 0.01 versus 8-CPT stimulation. Forsk., forskolin; T-CaMKII, total CaMKII.
or -arrestin2–YFP (Fig. 3 B, right) along with CaMKII-C and 
Flag-Epac1. Consistent with our in vivo experiments, ISO stim-
ulation resulted in a time-dependent increase in the association 
of Epac1, CaMKII, and -arrestin.
We next used confocal microscopy to determine whether 
-arrestin colocalizes with CaMKII and Epac1 and whether they 
traffic together in response to agonist. In the absence of ISO, 
CaMKII-C and -arrestin–YFP were colocalized in the cytosol, 577 -Arrestin links 1-AR–dependent CaMKII signaling • Mangmool et al.
-Arrestin is required for CaMKII-mediated 
phospholamban (PLB) phosphorylation
PLB serves as an important downstream effector of CaMKII in 
the heart (Bers, 2002). Therefore, we tested whether -arrestin 
is required for CaMKII-mediated phosphorylation of PLB in 
hearts  of  WT  and  -arrestin  KO  mice.  CaMKII  selectively 
phosphorylates PLB at Thr17, whereas PKA phosphorylates 
PLB at Ser16. After -AR stimulation with ISO, the level   
of PLB phosphorylation at Ser16 (PKA site) significantly   
increased in hearts of WT and -arrestin KO mice (Fig. 4 C, 
which redistributed to the plasma membrane after ISO stimu-
lation (Fig. 4 A, arrowheads). Similarly, Epac1 was uniformly 
distributed in the cytoplasm along with -arrestin, which trans-
located to the plasma membrane after ISO stimulation (Fig. 4 B, 
arrowheads). These data are in concordance with a recent study 
showing the rapid recruitment of Epac1 to the plasma mem-
brane after ISO stimulation (Ponsioen et al., 2009). Collectively, 
these results are consistent with our immunoprecipitation data 
showing that both -arrestin1 and -2 interact with CaMKII and 
Epac1 and traffic together in an agonist-dependent fashion.
Figure 3.  Interaction of CaMKII and Epac1 with -arrestins. (A) WT, -arrestin1 (-Arr1) KO, and -arrestin2 KO mice were administered with saline (NS), 
5 mg/kg ISO, or 2.5 mg/kg 8-CPT by i.v. infusion for 5 min. LV homogenates were immunoprecipitated with either anti-CaMKII or anti-Epac1 antibodies. 
Immunoprecipitated proteins were analyzed by Western blotting using the specific antibodies (n = 5). (B) HEK-293 cells stably expressing WT–1-AR were 
transiently transfected with CaMKII-C and Flag-Epac1, along with -arrestin1– (left) or -arrestin2–YFP (right). Serum-starved cells were stimulated with 
10 µM ISO for the indicated times at 37°C. Cell lysates were immunoprecipitated with either anti-CaMKII or anti-Epac1 antibodies. Immunoprecipitated 
proteins were analyzed by Western blotting using the specific antibodies (n = 5). ISO stimulation resulted in a time-dependent increase in the association 
of CaMKII and Epac1 with -arrestins. IP, immunoprecipitation.JCB • VOLUME 189 • NUMBER 3 • 2010   578
Figure 4.  ISO induced the translocation of CaMKII-C and Epac1 to plasma membrane and the phosphorylation of PLB at Thr17 site. (A and B) HEK-293 
cells stably expressing WT–1-AR were transiently transfected with CaMKII-C (A) or Flag-Epac1 (B), along with -arrestin1 (-Arr1)– (left) or -arrestin2– 
YFP (right). Serum-starved cells were stimulated with 10 µM ISO at 37°C. Dual labeling experiments were performed wherein cells were stained for CaMKII-C 
and Flag-Epac1 with Texas red, and -arrestin was visualized by YFP fluorescence. ISO stimulation resulted in marked redistribution of -arrestin–YFP 
together with CaMKII-C (A) or Flag-Epac1 (B) to the membrane (arrowheads). (C) WT, -arrestin1 KO, and -arrestin2 KO mice were administered 
with saline (NS), 5 mg/kg ISO, or 2.5 mg/kg 8-CPT by i.v infusion for 5 min. LV homogenates were immunoblotted with anti–phospho-PLB (p-PLB) at 
Ser16, anti–phospho-PLB at Thr17, and anti-PLB antibodies. The phosphorylation of PLB at Ser16 (bottom left) and Thr17 (bottom right) was quantified, 
expressed as fold increase over NS-treated WT mice, and shown as mean ± SEM (n = 5). KO of either -arrestin1 or -2 inhibited ISO- or 8-CPT–mediated   579 -Arrestin links 1-AR–dependent CaMKII signaling • Mangmool et al.
We next tested whether binding of -arrestin to the C-tail 
of the 1-AR induces -arrestin to adopt a unique conforma-
tion such that it can subserve CaMKII signaling. We used a 
bioluminescence  resonance  energy  transfer  (BRET)–based 
biosensor of -arrestin2 that detects structural changes of   
-arrestin2 in real time (Shukla et al., 2008). HEK-293 cells were 
transiently transfected with either WT or chimeric -ARs, along 
with the YFP–-arrestin2–Luc biosensor, and BRET was mea-
sured before and after ISO stimulation. Stimulation of either 
WT–1-AR or 2(1–7)/1(CT) chimeric receptors resulted in a 
threefold greater increase in BRET compared with that of WT– 
2-AR and 1(1–7)/2(CT) (Fig. 6 C). To exclude the possibil-
ity that the difference in BRET was caused by the amount of 
-arrestin bound to agonist-occupied receptors, we performed 
coimmunoprecipitation experiments and showed that the level 
of -arrestin bound to receptor was similar for each of the WT 
-ARs and the tail swap chimeric receptors (Fig. S2).
A possible explanation for the 1-AR–selective activation 
of CaMKII is that 1-ARs simply bind -arrestin with higher 
affinity than 2-ARs. To test this notion, we used a chimeric   
2-AR containing the C-tail of the vasopressin V2 receptor 
(V2R), which is known to have very high affinity and prolonged 
binding for -arrestin (Oakley et al., 1999). Although CaMKII 
activation occurred in cells expressing WT–1-ARs, stimulation 
of the 2-AR/V2 C-tail chimeric receptor with ISO or the WT 
V2R with vasopressin was unable to activate CaMKII (Fig. 6 D),   
despite robust recruitment of -arrestin to either agonist-occupied 
receptor (Fig. 6 E). Indeed, only 1-ARs could promote the 
agonist-induced scaffolding of Epac1 and CaMKII with -arrestin 
(Fig. 6 E). These data support our hypothesis that the C-tail 
of 1-AR mediates a unique conformation of -arrestin that 
allows for scaffolding of Epac and CaMKII to form a stable 
complex, leading to the subsequent cAMP/Epac-mediated ac-
tivation of CaMKII.
Interaction of CaMKII, Epac1, and  
-arrestins with 1-ARs
Our data suggest that the binding of -arrestin to the C-tail of 
1-ARs may trigger a unique -arrestin conformation that stabi-
lizes its binding of CaMKII and Epac as a multimeric complex. 
To test this hypothesis, we used Tg mice overexpressing Flag-
tagged WT–1-ARs (Noma et al., 2007) and measured the 
amount of CaMKII, Epac1, and -arrestin bound to immuno-
precipitated 1-ARs before and after ISO simulation. Stimu-
lation of 1-AR by ISO induced the recruitment of Epac, 
-arrestin, and CaMKII to agonist-occupied 1-ARs in heart 
tissue (Fig. 7 A).
We next examined whether the C-tail of 1-ARs is respon-
sible for binding of the CaMKII–-arrestin–Epac1 complex after 
agonist stimulation. Immunoprecipitation of only WT–1-ARs 
showed  ISO-induced  recruitment  of  Epac1,  -arrestin,  and 
CaMKII to the C-tail of agonist-occupied 1-ARs (Fig. 7 B). 
Importantly, ISO stimulation of 2-ARs still showed robust 
bottom left). 8-CPT, a cAMP analogue, is a selective activator 
of Epac and not PKA. It activates Epac1 with an EC50 = 2.2 µM, 
whereas the EC50 for PKA is >20 µM; Enserink et al., 2002). 
Consistent with this selective activity, we found that 8-CPT   
activated Epac to mediate CaMKII activation and phosphoryla-
tion of PLB at Thr17 (Fig. 4 C, bottom right) but had little activ-
ity  in  promoting  PKA-mediated  phosphorylation  of  PLB  at 
Ser16 (Fig. 4 C, bottom left). In contrast, PLB phosphorylation 
at Thr17 (CaMKII site) was significantly blunted in the -arrestin1 
and -2 KO mice after ISO or 8-CPT stimulation (Fig. 4 C,   
bottom right), indicating that -arrestin is necessary for down-
stream CaMKII signaling.
Stimulation of 1-ARs but not 2-ARs 
activates CaMKII signaling
Although it has recently been shown that stimulation of 1-ARs   
induces CaMKII activation in the heart (Zhu et al., 2003; Yoo 
et al., 2009), the mechanism by which only 1-ARs and not 
2-ARs mediates CaMKII signaling is unknown. With ISO stimu-
lation, pCaMKII significantly increased in hearts of WT and 
2-AR KO mice, whereas ISO had no effect on CaMKII activa-
tion in hearts from 1-AR KO or 1-, 2-AR double KO mice 
(Fig. 5 A). In contrast, direct stimulation of Epac with 8-CPT 
induced  CaMKII  activation  equally  in  hearts  from  1-AR 
KO, 2-AR KO, and 1-, 2-AR double KO mice. Similar to 
the in vivo heart experiments, HEK-293 cells stably expressing 
WT–1-ARs showed a time-dependent increase in pCaMKII 
with ISO stimulation (Fig. 5 B), whereas cells stably expressing 
2-ARs were unresponsive to ISO (Fig. 5 C). 8-CPT–mediated 
CaMKII phosphorylation occurred in both 1- and 2-AR stable 
HEK-293 cells (Fig. 5, B and C). These data show the subtype 
specificity  in  CaMKII  activation  solely  through  stimulation 
of 1-ARs. This observation is particularly puzzling because 
agonist stimulation of both -AR subtypes robustly activates 
AC to generate cAMP and should be able to activate Epac and 
CaMKII equally.
The C-tail of the 1-AR is required for  
ISO-mediated CaMKII activation
We reasoned that the selective activation of CaMKII by 1-ARs   
might be the result of its ability to recruit -arrestin and in-
duce a unique 1-AR–-arrestin conformation that promotes 
scaffolding of the Epac–CaMKII complex at the plasma mem-
brane. Because -arrestin is recruited to the C-tail of -ARs, 
we postulated that unique amino acid residues within the C-tail 
of the 1-ARs account for the -AR subtype specificity. To test 
this hypothesis, we used -AR chimeras in which the C-tail   
of the 1-AR was exchanged with the C-tail of the 2-AR   
(Fig. 6 A; Shiina et al., 2000). Only -ARs that contained the 
1-AR C-tail (i.e., WT–1-AR or 2(1–7)/1(CT)) were able 
to activate CaMKII signaling (Fig. 6 B), indicating the criti-
cal nature for amino acid residues within the C-tail of the 
1-AR in CaMKII activation.
PLB phosphorylation at Thr17. *, P < 0.01 versus NS-treated WT mice; 
#, P < 0.01 versus ISO-treated WT mice; 
‡, P < 0.01 versus 8-CPT–treated WT 
mice. T-PLB, total PLB. Bars, 10 µm.
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only -arrestin was found in complex with the 1(1–7)/2(CT) 
chimeric -AR (Fig. 7 D). Lastly, depleting -arrestin1/2 by 
siRNA eliminated the agonist-induced recruitment of all three 
proteins (CaMKII, Epac1, and -arrestin) to the 1-AR (Fig. 7 E). 
These data show that the recruitment of -arrestin specifically 
to the C-tail of 1-AR triggers a conformation in -arrestin that 
allows it to scaffold both CaMKII and Epac in a stable complex 
with the agonist-occupied receptor.
-arrestin translocation but failed to retain Epac1 and CaMKII 
in the immunoprecipitate (Fig. 7 C). Stimulation with 8-CPT 
was ineffective in recruiting Epac1, -arrestin, or CaMKII to 
either 1- or 2-ARs (Fig. 7, B and C). We used 1/2 chimeric 
receptors to determine whether the C-tail of the 1-AR instructs   
-arrestin to maintain CaMKII and Epac in a multimeric complex 
with the receptor. After ISO stimulation, CaMKII and Epac1 
robustly bound to the 2(1–7)/1(CT) chimeric -AR, whereas 
Figure 5.  Activation of CaMKII is mediated by 1-AR stimulation. (A) WT, 1-AR KO, 2-AR KO, and 1-, 2-AR double KO mice were administered with 
saline (NS), 5 mg/kg ISO, or 2.5 mg/kg 8-CPT by i.v. infusion for 5 min. LV homogenates were immunoblotted with anti-pCaMKII and anti-CaMKII anti-
bodies. The CaMKII activation was quantified, expressed as fold increase over NS-treated WT mice, and shown as mean ± SEM (n = 5). Stimulation of 
1-AR but not 2-AR activated CaMKII. *, P < 0.01 versus NS-treated WT mice; 
#, P < 0.01 versus ISO-treated WT mice. (B and C) HEK-293 cells stably 
expressing WT–1-AR (B) or WT–2-AR (C) were transiently transfected with CaMKII-C and Flag-Epac1. Serum-starved cells were stimulated with either 
10 µM ISO or 5 µM 8-CPT for the indicated times at 37°C (n = 5). Stimulation of 1-AR by ISO markedly increased CaMKII activity over a period of time, 
whereas 2-AR stimulation had no effect on CaMKII activation. IP, immunoprecipitation; T-CaMKII, total CaMKII.581 -Arrestin links 1-AR–dependent CaMKII signaling • Mangmool et al.
Figure 6.  The carboxyl terminus of 1-AR but not 2-AR is necessary for CaMKII activation and conformational changes of -arrestin. (A) Structure of 
chimeric 1/2-ARs. Dark and light lines indicate the peptide sequences derived from 1- and 2-AR, respectively. The 1(1–7)/2(CT) represents 1-AR 
containing the carboxyl terminus of 2-AR, whereas 2(1–7)/1(CT) represents 2-AR containing the carboxyl terminus of 1-AR. (B) HEK-293 cells were 
transiently transfected with WT–1-AR, 1(1–7)/2(CT), 2(1–7)/1(CT), or WT–2-AR, along with CaMKII-C and Flag-Epac1. Serum-starved cells were 
stimulated with 10 µM ISO at 37°C. The CaMKII activation was quantified, expressed as fold increase over nonstimulated WT–1-AR, and shown as mean ± SEM 
(n = 5). Increased ISO-mediated CaMKII activation was observed in cells expressing WT–1-AR and 2(1–7)/1(CT) chimeric receptors. *, P < 0.01 versus 
nonstimulation. (C) HEK-293 cells were transiently transfected with WT–1-AR, 1(1–7)/2(CT), 2(1–7)/1(CT), or WT–2-AR with -arrestin2 double bril-
liance biosensor (Luc–-arrestin2–YFP). The BRET ratio, which indicated the conformational change of -arrestin2, was determined. BRET was defined as 
the ISO stimulated ‒ nonstimulated BRET ratio, and data are shown as mean ± SEM (n = 5). *, P < 0.05 versus WT–1-AR. (D) HEK-293 cells were transiently 
transfected with WT–1-AR, WT–2-AR, 2/V2, or V2R, along with CaMKII-C and Flag-Epac1. Serum-starved cells were stimulated with 10 µM ISO or   
vasopressin at 37°C. The CaMKII activation was quantified, expressed as fold increase over nonstimulated WT–1-AR, and shown as mean ± SEM (n = 5).   
*, P < 0.01 versus nonstimulation. (E) HEK-293 cells were transiently transfected with CaMKII-C and Flag-Epac1, along with HA–1-AR, HA–2-AR, 
HA-2/V2, or HA-V2R. Serum-starved cells were stimulated with either 10 µM ISO or vasopressin at 37°C. -ARs were immunoprecipitated with anti-HA 
beads and immunoblotted for associated Epac1, -arrestin, and CaMKII (n = 5). IP, immunoprecipitation; T-CaMKII, total CaMKII.JCB • VOLUME 189 • NUMBER 3 • 2010   582
Figure 7.  CaMKII and Epac1 interact with the carboxyl terminus of 1-ARs. (A) Tg mice with cardiac-specific overexpression of mouse WT–1-AR   
(WT–1-AR Tg) were administered with saline (NS) or 5 mg/kg ISO by i.v. infusion for 5 min. LV homogenates were immunoprecipitated with anti-Flag 
antibody. Immunoprecipitated proteins were analyzed by Western blotting using the specific antibodies. Stimulation with ISO increased the amount of 
CaMKII, Epac1, and -arrestin binding with 1-AR in hearts. (B and C) HEK-293 cells were transiently transfected with CaMKII-C and Flag-Epac1, along 
with either HA–1-AR (B) or HA–2-AR (C). Serum-starved cells were stimulated with either 10 µM ISO or 5 µM 8-CPT for 10 min at 37°C. -ARs were 
immunoprecipitated with anti-HA beads and immunoblotted for associated Epac1, -arrestin, and CaMKII. ISO stimulation resulted in significant recruitment 
of Epac1, -arrestin, and CaMKII to 1-AR, whereas only -arrestin recruited to the 2-AR complex. (D) HEK-293 cells were transiently transfected with 
either 1(1–7)/2(CT) or 2(1–7)/1(CT) chimeric receptors, along with CaMKII-C and Flag-Epac1. Serum-starved cells were stimulated with 10 µM ISO 
for 10 min at 37°C. The receptor chimeras were immunoprecipitated with anti-HA beads and immunoblotted for associated Epac1, -arrestin, and CaMKII. 
The C-tail of 1-AR rather than 2-AR interacted with CaMKII and Epac1 after ISO stimulation. (E) HEK-293 cells were transfected with either control or   
-arrestin1/2 siRNA. HEK-293 cells were then transfected with HA–1-AR along with CaMKII-C and Flag-Epac1. Serum-starved cells were stimulated with 
10 µM ISO for 10 min at 37°C. 1-ARs were immunoprecipitated with anti-HA beads and immunoblotted for associated Epac1, -arrestin, and CaMKII. 583 -Arrestin links 1-AR–dependent CaMKII signaling • Mangmool et al.
Depletion of -arrestin1/2 inhibited ISO-induced recruitment of CaMKII and Epac1 to the 1-AR complex. Data illustrated in A–E are representative of five 
independent experiments. IB, immunoblot; IP, immunoprecipitation.
 
Because PDZ-binding motif (ESKV) facilitates the for-
mation of a cellular complex between 1-ARs and NMDA re-
ceptors (Hu et al., 2000), we tested whether the PDZ-binding 
motif is necessary for 1-AR–mediated CaMKII activation. Using 
1-ARs containing PDZ-binding motif mutants (S473A, S475A, 
S475D, or V477A) transfected into HEK-293 cells, we show 
that disruption of the PDZ-binding domain had no effect on 
ISO-mediated CaMKII phosphorylation (Fig. S3).
Discussion
In this study, we provide new insights into the molecular mech-
anism of CaMKII signaling. We demonstrate the requirement of 
-arrestin as a scaffold protein for CaMKII and Epac, whereby 
agonist stimulation results in the recruitment of this multimeric 
complex to the 1-AR. -Arrestin binding to the C-tail of 1-AR 
promotes a conformational change within -arrestin that allows 
CaMKII and Epac to remain in a stable complex when bound to 
agonist-occupied receptors. This unique -arrestin conforma-
tion induced by binding to the C-tail of 1-AR brings Epac and 
CaMKII in close proximity to the site of cAMP generation by 
the effector AC, which is required for the activation of CaMKII 
and downstream signaling. The essential role for -arrestin and 
identification of the molecular mechanism by which only the 
1-AR subtype activates CaMKII significantly advances our 
understanding of this important cellular pathway.
The arrestin family consists of four members. Visual   
arrestins (arrestin1 and -4) are expressed in the retina. The 
-arrestin1 and -2 (nonvisual arrestins, also known as arres-
tin2 and -3, respectively) are ubiquitously expressed and play 
a role in -AR internalization and trafficking (Ferguson, 2001). 
-AR stimulation leads to GRK-mediated receptor phosphory-
lation and the recruitment of -arrestins to phosphorylated 
-ARs, whereby -arrestins sterically inhibit further interaction 
between receptor and G proteins. Beyond their classical func-
tion, -arrestins also serve as scaffold proteins in receptor endo-
cytosis and signal transduction, linking receptors to several 
downstream effectors such as MAPK, Src, and the ubiquitin   
ligase Mdm2 (Lefkowitz and Shenoy, 2005). Previous studies 
have shown that -arrestin interacts with CaMKII- after AT1aR 
stimulation (Xiao et al., 2007) and with calmodulin (Wu et al., 
2006). We show in this study that -arrestins play a far greater 
role in CaMKII signaling by providing three critical functions: 
(1) to scaffold CaMKII and Epac in the cytoplasm, (2) to trans-
locate this multimeric complex to the plasma membrane after   
-AR stimulation and bring Epac and CaMKII in close proxim-
ity to the site of cAMP generation, and (3) to adopt a conforma-
tion that maintains high affinity binding between -arrestin and 
the agonist-occupied 1-AR, CaMKII, and Epac. CaMKII sig-
naling appears to use both -arrestin1 and -2 because elimina-
tion of either isoform in cells by siRNA, or in mice by gene 
targeting, significantly diminishes CaMKII activation. This 
dual -arrestin requirement might reflect distinct roles played 
by each isoform or perhaps the requirement for heterodimeriza-
tion of -arrestin1 and -2 (Lefkowitz et al., 2006).
-Arrestins can exist as homo- and heterooligomers (Storez 
et al., 2005; Milano et al., 2006) and raise the possibility that 
-arrestin oligomers may be involved in the regulation of their 
cellular distribution and function. In contrast, only monomeric 
visual arrestin binds to rhodopsin (Hanson et al., 2007a,b), and 
when arrestins mobilize MAPKs to a receptor, it is the nonreceptor-
binding side of arrestin that is available for interaction with 
kinases (Gurevich et al., 2008). Our data demonstrating that both 
-arrestin1 and -2 are involved in CaMKII activation are consis-
tent with the codependence of both -arrestins in other receptor 
systems in which heterooligomerization has been offered as a 
possible explanation (DeWire et al., 2007). Nonetheless, it re-
mains an unsolved question whether -arrestins bound to agonist-
occupied -ARs exist as homo- or heterodimers.
Previous  studies  have  identified  a  family  of  molecules 
known as Epacs that directly bind cAMP and exhibit guanine 
nucleotide exchange factor activity toward Rap1 (de Rooij   
et al., 1998; Bos, 2006). Translocation of Epac to the plasma 
membrane by ISO stimulation was recently shown in several 
cell types, indicating the important spatial control of Epac by 
cAMP (Ponsioen et al., 2009). There are two subtypes of Epac, 
Epac1 and -2. Epac1 is mainly expressed in human heart, is in-
creased in heart failure, and promotes CaMKII activity after   
-AR stimulation in a PKA-independent fashion (Métrich et al., 
2008). Activation of Epac by cAMP or with the selective cAMP 
analogue  8-CPT  leads  to  CaMKII-dependent  stimulation  of   
SR Ca
2+ release and diastolic SR Ca
2+ leak (Oestreich et al., 
2007; Pereira et al., 2007).
The mechanism by which Epac activates CaMKII appears 
to require the presence of Rap, PLC-, and PKC- (Oestreich   
et al., 2007, 2009). Indeed, it has been shown that the Ras   
family members Rap1 and -2 mediate translocation of PLC- 
to the membrane and enhance PLC- activity (Song et al., 
2001; Bunney and Katan, 2006). Enzymatic activity of PLC- 
results in effector signaling by producing DAG and inositol 
1,4,5-triphosphate  as  second  messengers. Accumulation  of 
DAG also leads to DAG-dependent translocation of PKC-  
to the membrane (Stahelin et al., 2005; Escribá et al., 2007).   
Although it is likely that Rap, PLC-, and PKC- are involved 
in the activation of CaMKII after 1-AR stimulation, it will   
require further study to determine the precise molecular details 
of this pathway and whether any of these proteins are assembled 
within a -arrestin–Epac–CaMKII complex.
Interestingly, it has been reported that stimulation of   
2-ARs can activate a cAMP–Epac–RapGTP–PLC- pathway 
(Schmidt et al., 2001). However, our data clearly show that only 
1-ARs and not 2-ARs are able to stimulate CaMKII. In con-
trast, -arrestin binding to 2-AR induces a -arrestin confor-
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could promote stable association of CaMKII and Epac with   
-arrestin at the plasma membrane. Thus, the recruitment   
of -arrestins alone to agonist-occupied receptors is not suffi-
cient to promote -AR–mediated CaMKII activation but requires 
a unique 1-AR–mediated conformational change in -arrestin 
that is triggered by -arrestin binding to the 1-AR C-tail. We 
hypothesize that a conformational change in -arrestin upon 
recruitment to the 1-AR increases the affinity of CaMKII 
and Epac1 to -arrestin, which tethers Epac and CaMKII in a 
cAMP microdomain, triggering CaMKII activation. Our data 
are consistent with a recent study showing that the interaction 
of calmodulin with the proximal region of the serotonin recep-
tor carboxyl terminus is important for arrestin-dependent ERK 
signaling (Labasque et al., 2008).
Based on the data from our experiments, we propose an 
essential role for -arrestin in mediating CaMKII signaling   
after 1-AR stimulation (Fig. 8). Agonist binding to 1-ARs 
leads to G protein–mediated activation of AC and cAMP gener-
ation. Promptly thereafter, the stimulation of 1-ARs by agonist 
leads to GRK-mediated receptor phosphorylation and -arrestin   
recruitment. The unique conformational change induced in   
-arrestin by binding to 1-ARs allows for a strong interaction 
with CaMKII and Epac, maintaining these proteins in complex 
at the plasma membrane. Stimulation of AC activity increases 
the level of cAMP in the 1-AR–-arrestin–Epac–CaMKII   
microdomain.  cAMP  directly  binds  to  and  stimulates  Epac, 
which in turn appears to stimulate Rap–PLC-–PKC-, leading 
to the activation of CaMKII. In contrast, -arrestin binding to 
2-ARs induces a -arrestin conformation that does not pro-
mote a stable complex with Epac and CaMKII, and therefore, 
no CaMKII signaling occurs.
with -arrestin at the plasma membrane. As we show in this 
study, an important component to this signaling pathway is the 
assembly of a multimeric complex scaffolded by -arrestin,   
which allows for Epac and CaMKII to be held in structural 
proximity and be brought to the plasma membrane after -AR 
stimulation. In the absence of -arrestin, CaMKII and Epac are 
unable to maintain this protein–protein interaction and lose the 
ability to be activated by -AR agonists.
Although both 1- and 2-ARs can couple to the G protein Gs,   
there are several differences in their functional properties 
that lead to subtype-specific activation of signaling pathways 
(Xiao et al., 2006). Even though 1- and 2-AR share 54% 
sequence identity, the C-tail of these receptors plays a differ-
ential role in receptor endocytosis and signal transduction. For 
example, the binding of -arrestin1 and -2 to the third intra-
cellular loop and the C-tail of the 1-AR is lower than that for 
the 2-AR (Shiina et al., 2000). A chimeric 2-AR containing   
the C-tail region of 1-AR loses its ability to promote -arrestin2– 
mediated ERK nuclear translocation (Kobayashi et al., 2005). 
Moreover, the PDZ-binding motif of the 2-AR C-tail inter-
acts with NHERF (Hall et al., 1998), whereas NMDA recep-
tors bind to an ESKV motif within the C-tail of the 1-AR 
(Hu et al., 2000). In this study, we provide new mechanistic 
information for the role of 1-ARs in CaMKII signaling in 
response to catecholamine stimulation. Stimulation of 1-ARs 
augments the association of CaMKII and Epac1 with -arrestins.   
This multimeric protein complex, which then translocates to 
plasma membrane, binds to the 1-AR C-tail and forms a sta-
ble protein–protein complex secondary to a conformational 
change in -arrestin. Remarkably, despite the strong agonist-
dependent binding of -arrestin to 2-ARs and V2Rs, neither 
Figure 8.  Schematic diagram representing the essential role of -arrestin for CaMKII signaling. Agonist binding to 1-ARs leads to G protein coupling, 
cAMP generation, and activation of PKA signaling. GRK-mediated receptor phosphorylation results in -arrestin recruitment, which induces a unique confor-
mation in -arrestin allowing stable interaction with CaMKII and Epac at the plasma membrane. -Arrestin–mediated translocation of CaMKII and Epac to 
the 1-AR complex brings these molecules in close proximity to the location of cAMP generation by AC. cAMP directly binds to and stimulates Epac, which 
leads to CaMKII activation via a Rap–PLC-–PKC- mechanism, and subsequent phosphorylation of downstream effectors.585 -Arrestin links 1-AR–dependent CaMKII signaling • Mangmool et al.
Confocal microscopy
Confocal microscopy was performed as described previously (Mangmool 
et al., 2006). In brief, HEK-293 cells stably expressing WT–1-AR trans-
fected with either -arrestin1– or -arrestin2–YFP together with either   
CaMKII-C or Flag-Epac1 were plated on 35-mm glass-bottomed culture 
dishes. After stimulation with ISO at 37°C, cells were washed once with 
PBS, fixed in 4% paraformaldehyde, permeabilized in 0.1% Triton X-100, 
and  stained  using  Texas  red  fluorescent–labeled  secondary  antibodies 
against either CaMKII- or Epac1. Colocalization of -arrestins with either 
CaMKII-C or Epac1 was performed using dual excitation (488 nm for YFP 
and 543 nm for Texas red) of a laser-scanning microscope (LSM-510M; 
Carl Zeiss, Inc.) with a Plan-Apochromat 100× NA 1.4 objective lens (Carl 
Zeiss, Inc.) and observed at room temperature. The image analysis was 
determined using LSM-510 software (Carl Zeiss, Inc.).
siRNA experiments targeting -arrestins
To design -arrestin–specific siRNA duplexes, the mRNA sequences for 
human -arrestin1 and -2 were screened for unique 21-nt sequences in the 
National Center for Biotechnology Information database using the BLAST 
search algorithm. The siRNA sequences targeting -arrestin1 (GenBank/
EMBL/DDBJ  accession  no.  NM_020251)  and  -arrestin2  (GenBank/
EMBL/DDBJ accession no. NM_004313) have been previously described 
(Ahn et al., 2003). A nonsilencing RNA duplex (5-AAUUCUCCGAAC-
GUGUCACGU-3) was used as a control. 30–40% confluent HEK-293 
cells stably expressing WT–1-AR were transfected with 100 nM -arrestin 
siRNA or control siRNA using GeneSilencer Transfection reagent (Gene 
Therapy Systems) according to the manufacturer’s instructions. In brief, 5 µl 
of  transfection  reagent  was  added  to  45  µl  Opti-MEM  I  (Invitrogen), 
whereas 100 nM of siRNA duplex was mixed with 45 µl Opti-MEM I. Both 
solutions were allowed to stand 5–10 min at room temperature and mixed 
by inversion. After 20 min of incubation, the entire transfection mixture was 
added to cells in a 10-cm dish containing 4 ml of fresh, serum-free DME. 
After cells were incubated for 5 h at 37°C and 5% CO2, transfection   
medium was replaced with the original conditioned medium. All assays 
were performed at least 3 d after siRNA transfection.
CaMKII activity assay
CaMKII activity of ventricular homogenates was measured with a CaMKII 
assay kit (Millipore) using a specific peptide substrate (KKALRRQETVDAL) 
as previously described (Yoo et al., 2009). In brief, left ventricular (LV) ho-
mogenate (1 mg protein) was first immunoprecipitated with anti-CaMKII anti-
body (Santa Cruz Biotechnology, Inc.). Samples were incubated in reaction 
buffer containing the CaMKII peptide substrate and 0.5 µCi -[
32P]ATP in 
a total volume of 50 µl. The reactions were performed at 30°C for 20 min 
and were terminated by chilling on ice. Equal amounts of reaction products 
were blotted on membrane and washed with 1% HCl to remove unincorpo-
rated isotope. CaMKII activity was analyzed by scintillation counting and 
normalized to protein concentration.
Western blotting
After stimulation, cells were washed once with PBS and solubilized in lysis 
buffer containing 20 mM Tris-HCl, pH 7.4, 0.8% Triton X-100, 150 mM   
NaCl, 2 mM EDTA, 10% glycerol, 100 µM PMSF, 5 µg/ml aprotinin, and   
5 µg/ml leupeptin. Protein concentration of LV homogenates and cell   
lysates was determined using a protein assay kit (Bio-Rad Laboratories) 
with bovine serum albumin as standard. Samples were mixed with load-
ing buffer and denatured by heating at 95°C for 5 min before separa-
tion by SDS-PAGE. Separated proteins were transferred to polyvinylidene 
fluoride membrane (Bio-Rad Laboratories) and subjected to immunoblot-
ting  with  various  primary  antibodies  to  CaMKII  (1:2,000;  Santa  Cruz 
Biotechnology, Inc.), CaMKII- (1:2,000; Santa Cruz Biotechnology, Inc.), 
pCaMKII (Thr286/287; 1:2,000; Cell Signaling Technology), pCaMKII 
(Thr286/287;  1:2,000;  Millipore),  PLB  (1:2,000;  Santa  Cruz  Biotech-
nology, Inc.), phospho-PLB (Ser16 or Thr17; 1:2,000; Santa Cruz Bio-
technology, Inc.), -arrestin (1:2,000; BD), -arrestin (1:3,000; gift from 
R.J. Lefkowitz), Flag (1:2,000; Sigma-Aldrich), HA (1:2,000; BD), 1-AR 
(1:2,000; Santa Cruz Biotechnology, Inc.), and 2-AR (1:2,000; Santa 
Cruz Biotechnology, Inc.). Although both -arrestin isoforms could be de-
tected in HEK-293 cells, only -arrestin1 was reliably detected in the heart 
(Fig. S4). Immunoblots were visualized with an HRP-conjugated secondary 
antibody and a chemiluminescence detection system (GE Healthcare).
Immunoprecipitation
Protein concentration of LV homogenates and cell lysates was determined 
using a Bio-Rad Laboratories protein assay kit with bovine serum albumin 
CaMKII appears to play an important pathogenic role in 
the development of heart failure (Anderson, 2009). CaMKII 
activity is increased in heart failure patients (Gwathmey et al., 
1987) and in animal models after myocardial infarction and   
-AR stimulation (Yoo et al., 2009). Inhibition of CaMKII 
activity using a dominant-negative strategy (Zhang et al., 2005) 
or CaMKII- gene ablation (Ling et al., 2009) prevents cardiac 
dilation and dysfunction after myocardial infarction or pres-
sure overload. Although -AR stimulation serves as a power-
ful regulatory mechanism to augment contractility (Rockman   
et al., 2002), excessive -AR stimulation causes adverse cardiac 
remodeling that appears to be predominantly mediated by the   
1-AR subtype (Yoo et al., 2009). Our data support a concept 
whereby excessive 1-AR stimulation promotes a pathologi-
cal process, in part, through its activation of CaMKII signaling 
(Zhu et al., 2003, 2007; Wang et al., 2004; Yoo et al., 2009).
In conclusion, we have identified a new signaling mecha-
nism for CaMKII activation regulated by -arrestins. Activation 
of CaMKII after 1-AR stimulation requires the scaffolding of 
CaMKII and Epac by -arrestin, allowing translocation of this 
multimeric protein complex to agonist-occupied 1-ARs, which 
leads to activation of the -arrestin–mediated CaMKII signal-
ing pathway.
Materials and methods
Reagents and plasmid construction
8-CPT was purchased from Tocris Bioscience. Forskolin, ()-ISO hydrochlo-
ride, and anti-Flag M2 agarose were purchased from Sigma-Aldrich. PKI 
and KN-92 and -93 were purchased from EMD. -[
32P]ATP was purchased 
from PerkinElmer. FuGENE 6 and anti-HA affinity matrix were purchased from 
Roche. Coelenterazine h was purchased from Promega. Plasmids encod-
ing -arrestin1–YFP, -arrestin2–YFP, and 1-AR PDZ-binding motif mutants 
(S473A, S475A, S475D, and V477A) were obtained from R.J. Lefkowitz   
(Duke University Medical Center, Durham, NC). Plasmid encoding Luc– 
-arrestin2–YFP was obtained from M. Bouvier (Université de Montréal, Mon-
tréal, Québec, Canada). Plasmid encoding CaMKII-C was obtained from   
G.S. Pitt (Duke University Medical Center). Plasmid encoding Flag-tagged 
Epac1 was obtained from A.V. Smrcka (University of Rochester, Rochester, NY). 
Plasmids encoding HA-tagged chimeric 1(1–7)/2(CT) and 2(1–7)/1(CT) 
-ARs were a gift from H. Kurose (Kyushu University, Fukuoka, Japan).
Cell culture and transient transfection
HEK-293 cells and HEK-293 cells stably expressing WT–1-AR, GRK
–1-AR, 
and WT–2-AR were cultured as described previously with minor modifica-
tions (Naga Prasad et al., 2001). Cells were maintained in either DME 
or minimal essential medium supplemented with 10% fetal bovine serum 
and 1:100 penicillin-streptomycin (10,000 U/ml) at 37°C. The cells were 
seeded at a density of 10
5 cells for 35-mm confocal dishes or 10
6 cells 
for  10-cm  dishes  before  the  day  of  transfection.  Appropriate  amounts 
of plasmids (2 µg/35-mm confocal dish, 2 µg/well of 6-well dish, or   
4–6 µg/10-cm dish) were used for transient transfection with FuGENE 6 
according to the manufacturer’s instructions. Cells were used for assays 2 d 
after transfection. Under serum starvation conditions, cells were stimulated 
with 10 µM ISO or 5 µM 8-CPT for the indicated time.
Treatment protocol for mice
The animals in this study were handled according to approved protocols 
and animal welfare regulations of the authors’ Institutional Review Boards. 
-Arrestin KO mice were provided by R.J. Lefkowitz. -AR KO mice were 
provided by B.K. Kobilka (Stanford University, Stanford, CA). Mice were 
administered saline, 5 mg/kg ISO, or 2.5 mg/kg 8-CPT by i.v. infusion. 
5 min after ISO or 8-CPT administration, hearts were excised and flash-
frozen in liquid N2 for biochemical assays. Hearts were homogenized in 
lysis buffer containing 20 mM Tris-HCl, pH 7.4, 2 mM EDTA, 1% Nonidet 
P-40, 10 mM NaF, 1mM Na3VO4, 20% glycerol, 100 µM PMSF, 5 µg/ml 
aprotinin, and 5 µg/ml leupeptin.JCB • VOLUME 189 • NUMBER 3 • 2010   586
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as standard. Immunoprecipitation was performed by overnight incubation/ 
rotation with 2 µg of rabbit polyclonal anti-Epac (Santa Cruz Biotechnol-
ogy, Inc.), goat polyclonal anti-CaMKII (Santa Cruz Biotechnology, Inc.), 
or rabbit polyclonal anti–-arrestin antibodies (gift from R.J. Lefkowitz). 
The  control  (no  antibody)  was  also  included  for  each  sample.  After 
incubation, protein A/G plus agarose beads was added to immunopre-
cipitated samples and rotated for 2 h with rotation. Beads were washed 
twice with lysis buffer, once with PBS. Bound proteins were eluted by the 
addition of SDS loading buffer and analyzed by Western blotting using 
the indicated antibodies.
BRET assay
BRET  assays  were  performed  as  described  previously  (Charest  et  al., 
2005; Shukla et al., 2008). In brief, 48 h after transfection, HEK-293 cells 
coexpressing the WT and chimeric -ARs and Luc–-arrestin2–YFP were 
detached with PBS/EDTA. Approximately 5 × 10
5 cells per well were 
plated in a 96-well white microplate. The cells were incubated with 5 µM 
coelenterazine h for 10 min and subsequently stimulated with 10 µM ISO 
at 25°C for the indicated time period, and readings were collected imme-
diately by using a microplate reader (Mithras LB940; Berthold Technolo-
gies). The BRET signal was determined as the ratio of the light emitted by 
YFP and the light emitted by Luc. The values were corrected by subtracting 
the background BRET signals. BRET was defined as the ISO stimulated ‒ 
nonstimulated BRET ratio.
Statistics
Data are expressed as mean ± SEM. Statistical analyses were determined 
using one-way analysis of variance. Differences were considered statisti-
cally significant at P < 0.05.
Online supplemental material
Fig. S1 demonstrates that -arrestin associates with Epac1 in CaMKII- 
KO mice. Fig. S2 shows that the level of -arrestin bound to receptor is 
similar for each of the WT -ARs and the tail swap chimeric receptors.   
Fig. S3 demonstrates that disruption of the PDZ-binding motif of 1-ARs 
had no influence of ISO-mediated CaMKII phosphorylation. Fig. S4 shows 
the level of -arrestin expression in hearts obtained from -arrestin1 and -2 
KO mice. Online supplemental material is available at http://www.jcb 
.org/cgi/content/full/jcb.200911047/DC1.
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